Among a further generation of CD40L antagonists under development, a PEGylated anti-CD40L antibody fragment has been evaluated in a phase 1, single-ascending-dose study of healthy individuals and participants with lupus and has shown predictable pharmacokinetics and acceptable tolerability without any thrombotic events31. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.